Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us  
Google
Web www.equitybulls.com
Stock Report

| More

Emcure Pharmaceuticals signs agreement with Gilead for the Manufacture and Global Supply of Lenacapavir

Posted On: 2024-10-03 19:32:40 (Time Zone: IST)


Emcure Pharmaceuticals, a leading Indian pharma company announces the signing of a royalty-free voluntary licensing agreement with Gilead Sciences Ireland UC, part of California, US based Gilead Sciences to manufacture and supply generic versions of lenacapavir. This agreement is part of a broader effort to increase global access to lenacapavir for HIV prevention and treatment, with a focus on high-incidence, resource-limited countries.

Emcure will play a crucial role in ensuring the availability of high-quality, low-cost versions of lenacapavir in 120 countries, primarily in low- and lower-middle-income regions. This strategic partnership underscores Emcure's commitment to innovative affordable global healthcare.

Commenting on the development, Satish Mehta, Managing Director and CEO, Emcure Pharmaceuticals Ltd., said, "We are proud to partner with Gilead in this global initiative to expand access to critical HIV medicines. As the leader in HIV antiviral segment in covered market in India with long standing experience in supplying HIV medicines to over 100 LMIC countries, Emcure is uniquely positioned to drive impactful change in the global fight against HIV. By bringing lenacapavir to the regions that need it most, we are taking a step forward in improving health outcomes worldwide."

Emcure's commitment to affordability and quality is backed by its expertise in manufacturing complex generic drugs. This partnership highlights Emcure's role as a leading manufacturer of generic pharma products and its commitment to innovative and affordable healthcare globally.

About Lenacapavir:

Lenacapavir is approved in multiple countries for the treatment of adults with multi-drug resistant HIV in combination with other antiretrovirals. The use of lenacapavir for HIV prevention is investigational and the safety and efficacy of lenacapavir for this use have not been established.

The multi-stage mechanism of action of lenacapavir is distinguishable from other currently approved classes of antiviral agents. While most antivirals act on just one stage of viral replication, lenacapavir is designed to inhibit HIV at multiple stages of its lifecycle and has no known cross resistance exhibited in vitro to other existing drug classes.

Lenacapavir is being evaluated as a long-acting option in multiple ongoing and planned early and latestage clinical studies in Gilead's HIV prevention and treatment research program. Lenacapavir is being developed as a foundation for potential future HIV therapies with the goal of offering both long-acting oral and injectable options with several dosing frequencies, in combination or as a mono agent, that help address individual needs and preferences of people and communities affected by HIV.

Shares of Emcure Pharmaceuticals Limited was last trading in BSE at Rs. 1493.75 as compared to the previous close of Rs. 1474.75. The total number of shares traded during the day was 5707 in over 813 trades.

The stock hit an intraday high of Rs. 1508.00 and intraday low of 1438.00. The net turnover during the day was Rs. 8495100.00.


Click here to send ur comments or to feedback@equitybulls.com





Other Headlines:

RailTel Corporation of India Ltd receives order worth Rs. 36.78 crores

Triveni Engineering & Industries Ltd. forays into IMFL segment

MAZAGON DOCK SHIPBUILDERS LIMITED declares interim dividend of Rs. 23.19

Oriental Rail Infrastructure Ltd receives order worth Rs. 1.11 crore

Systematix Corporate Services Ltd fixes Nov 5, 2024 as record date for 10 For 1 Stock Split

NHPC Ltd announces loss due to damage at Teesta-V Power Station

Gulshan Polyols Ltd allocated Ethanol supply order by OMCs

Choice Finserv to acquire NBFC and Loan Distribution Portfolios, AUM to increase by 75%

Firstsource to build domain-centric Large Language Model for the U.S Mortgage Business

ALT Digital Media Entertainment Ltd clarifies on web series - Gandi Baat

Imagicaaworld Entertainment Limited to reopen Aqua Imagicaa at Surat

Sonata Software wins Multi-Year AI-Powered Managed Services Contract from Fortune 500 Manufacturing Company

Triveni Engineering & Industries Ltd. Launched Premium and Super Premium Whisky Brands

MAZAGON DOCK SHIPBUILDERS LIMITED approves 2 For 1 Stock Split

John Cockerill India Ltd receives order from fellow subsidiary

EaseMyTrip and Cars24 joins hands to offer customers a chance to win a free car

Happiest Minds positioned as a 'Major Contender' in Everest Group's Cybersecurity PEAK Matrix® Assessment - North America 2024

50 years of CERELAC in India, announces the introduction of CERELAC no refined sugar recipes

Metacast Auto Pvt Ltd to commence business operations shortly

Ambuja Cements Ltd to acquire Orient Cement Limited

Advait Infratech Ltd is now Advait Energy Transitions Ltd

Spectrum Foods Ltd. Signs Non-Binding LOI With IHG for Pushkar Project

SBC Exports Ltd consolidated Q2FY25 profit at Rs. 5.36 crores

Swastika Investmart Ltd consolidated Q2 FY2024-25 profit up at Rs. 7.23 crores

TCC Concept Ltd posts rise in Q2FY25 consolidated PAT to Rs. 9.27 crores

Orbit Exports Ltd Q2 FY2025 consolidated PAT jumps to Rs. 15.99 crores

IIFL Securities Ltd Q2 FY2024-25 consolidated net profit higher at Rs. 205.05 crores

Max Financial Services Ltd reports consolidated net profit of Rs. 112.56 crores in Q2FY25

Prime Securities Ltd Q2 FY2025 consolidated profit rises to Rs. 17.20 crores

Ugro Capital Ltd Q2 FY2024 PAT climbs to Rs. 35.52 crores

Indus Towers Ltd posts consolidated Q2 FY2024-25 net profit of Rs. 2223.5 crores

Tokyo Finance Ltd Q2 FY2025 PAT at Rs. 10.20 lakhs

Can Fin Homes Ltd reports net profit of Rs. 211.48 crores in Q2 FY25

Shoppers Stop Ltd posts consolidated loss of Rs. 20.59 crores in Q2 FY2025

RO Jewels Ltd Q2 FY2025 profit at Rs. 8.22 lakhs

ICICI Prudential Life Insurance Company Ltd consolidated Q2FY25 PAT up at Rs. 250.99 crores

Gabriel India Ltd Q2 FY25 consolidated profit at Rs. 62.91 crores

Olectra Greentech Ltd Q2 FY25 consolidated PAT jumps to Rs. 47.56 crores

Vikas Lifecare Ltd Q2 FY2025 consolidated PAT at Rs. 2.38 crore

Osiajee Texfab Ltd consolidated Q2FY25 profit higher at Rs. 52.77 lakhs

Gujarat Mineral Development Corporation Ltd Q2 FY2024-25 consolidated net profit slips QoQ to Rs. 127.86 crores

Bajaj Finance Ltd consolidated Q2FY25 net profit rises to Rs. 3999.73 crores

Dynamic Cables Ltd Q2 FY2025 net profit higher at Rs. 13.85 crores

Cigniti Technologies Ltd posts consolidated PAT of Rs. 52.94 crores in Q2 FY25

Responsive Industries Ltd consolidated Q2FY25 net profit higher at Rs. 49.28 crores

Chennai Petroleum Corporation Ltd consolidated Q2FY25 loss at Rs. 633.69 crores

Jindal Hotels Ltd Q2 FY2024-25 loss at Rs. 1.43 crore

Royale Manor Hotels and Industries Ltd Q2 FY2025 profit increases QoQ to Rs. 40.31 lakhs

Choice International Ltd Q2 FY2025 consolidated PAT climbs to Rs. 46.45 crores

Bridge Securities Ltd Q2FY25 profit at Rs. 1 crore


Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2020